Troponin I and T in relation to cardiac injury detected with electrocardiography in a population-based cohort - The Maastricht Study

Dorien M. Kimenai1,2, Remy J. H. Martens3,4, Jeroen P. Kooman3,4, Coen D. A. Stehouwer2,5,6, Frans E. S. Tan7, Nicolaas C. Schaper2,5, Pieter C. Dagnelie2,6,8, Miranda T. Schram2,5,9, Carla J. H. van der Kallen2,5, Simone J. S. Sep2,5, Jeroen D. E. van Suijlen10, Abraham A. Kroon2,5, Otto Bekers1,2, Marja P. van Dieijen-Visser1,2, Ronald M. A. Henry2,5,9 & Steven J. R. Meex1,2

Interest in high-sensitivity cardiac troponin I (hs-cTnI) and T (hs-cTnT) has expanded from acute cardiac care to cardiovascular disease (CVD) risk stratification. Whether hs-cTnI and hs-cTnT are interchangeable in the ambulant setting is largely unexplored. Cardiac injury is a mechanism that may underlie the associations between troponin levels and mortality in the general population. In the population-based Maastricht Study, we assessed the correlation and concordance between hs-cTnI and hs-cTnT. Multiple regression analyses were conducted to assess the association of hs-cTnI and hs-cTnT with electrocardiographic (ECG) changes indicative of cardiac abnormalities. In 3016 eligible individuals (mean age, 60 ± 8 years; 50.6%, men) we found a modest correlation between hs-cTnI and hs-cTnT (r = 0.585). After multiple adjustment, the association with ECG changes indicative of cardiac abnormalities was similar for both hs-cTnI (OR, hs-cTnI: 1.72, 95% CI: 1.40–2.10; OR, hs-cTnT: 1.60, 95% CI: 1.22–2.11). The concordance of dichotomized hs-cTnI and hs-cTnT was κ = 0.397 (≥ sex-specific 75th percentile). Isolated high levels of hs-cTnI were associated with ECG changes indicative of cardiac abnormalities (OR: 1.93, 95% CI: 1.01–3.68), whereas isolated high levels of hs-cTnT were not (OR: 1.07, 95% CI: 0.49–2.31). In conclusion, there is a moderate correlation and limited concordance between hs-cTnI and hs-cTnT under non-acute conditions. These data suggest that associations of hs-cTnI and hs-cTnT with cardiac injury detected by ECG are driven by different mechanisms. This information may benefit future development of CVD risk stratification algorithms.

The cardiac troponins I and T are the preferred biomarkers for diagnosing acute myocardial infarction (AMI). Whereas conventional troponin assays were limited to the detection of plasma troponin concentrations that are typically seen in the setting of acute cardiac injury, high-sensitivity assays can detect cardiac troponin concentrations below the clinical cut-off levels. In parallel with this technical progress, interest in cardiac troponin has expanded from acute cardiac care to cardiovascular disease (CVD) risk stratification. Indeed, epidemiological

---

1Department of Clinical Chemistry, Central Diagnostic Laboratory, Maastricht University Medical Center+ (MUMC+), Maastricht, The Netherlands. 2CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands. 3Department of Internal Medicine, Division of Nephrology, MUMC+, Maastricht, The Netherlands. 4NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands. 5Department of Internal Medicine, MUMC+, Maastricht, The Netherlands. 6CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands. 7Department of Methodology and Statistics, Maastricht University, Maastricht, The Netherlands. 8Department of Epidemiology, MUMC+, Maastricht, The Netherlands. 9Heart and Vascular Centre, MUMC+, Maastricht, The Netherlands. 10Department of Clinical Chemistry, Gelre Hospital, Apeldoorn, The Netherlands. Correspondence and requests for materials should be addressed to S.J.R.M. (email: steven.meex@mumc.nl)
studies have demonstrated that basal levels of high-sensitivity cardiac troponin I (hs-cTnI) and T (hs-cTnT) are invariably associated with cardiac morbidity and mortality, even in apparently healthy individuals. Whether hs-cTnI and hs-cTnT are interchangeable in CVD risk stratification algorithms is largely unexplored. An important issue here is the fact that, although during and after AMI, hs-cTnI and hs-cTnT levels in blood are strongly correlated (reported \(r = 0.85\)) and carry equivalent diagnostic value, they do not so under non-acute conditions (reported \(r = 0.44–0.70\)). This surprising discrepancy may suggest different mechanisms of release or clearance for troponin I and T in the chronic setting, but more importantly, it raises the hypothesis that associations of cardiac troponin I and T with cardiac morbidity and mortality may be different.

Cardiac injury is a plausible mechanism that may underlie the associations between basal troponin levels and cardiac morbidity and mortality in the general population, and more insight in the relationship between cardiac troponin I and T with cardiac morbidity and mortality may be different. 

Results

Study population. A total of 3016 eligible participants from The Maastricht Study cohort were included in the present study (see Supplementary Fig. S1). Clinical characteristics of the total study population, and stratified by the presence of ECG changes indicative of cardiac abnormalities, are shown in Table 1. The overall proportion of participants with detectable hs-cTnI levels (Limit of Detection (LoD) \(\geq 5\) ng/L) was 54%. The overall proportion of detectable hs-cTnI levels ranged from 51% (LoD \(\geq 1.9\) ng/L) to 83% (LoD \(\geq 1.1\) ng/L). The overall proportion of participants with hs-cTn levels above the 10% coefficient of variation (CV) for hs-cTnI and hs-cTnT were 6% and 10%, respectively. CVD risk factors were more prevalent in participants with ECG changes indicative of cardiac abnormalities as compared with participants without ECG changes indicative of cardiac abnormalities (Table 1). The number (%) of Minnesota coding categories of ECG abnormalities of the total study population are shown in Supplementary Table S1.
Modest correlation between hs-cTnI and hs-cTnT. In contrast to the acute cardiac care setting where troponin I and T are interchangeable, a remarkably modest correlation was found between hs-cTnI and hs-cTnT in these ambulatory participants (r = 0.585, 95% CI 0.562–0.608, p < 0.001, Fig. 1). The modest correlation was not due to discrepant sensitivities of hs-cTn assays. In the analyses we corrected for the proportion of participants below the LoB, and even after excluding participants with hs-cTn below the LoD (LoD hs-cTnI: 1.9 ng/L, LoD hs-cTnT: 5 ng/L), which equalized the proportion of participants with detectable hs-cTnT levels to those of the hs-cTnI assay, the correlation did not improve (r = 0.373, 95% CI 0.322–0.420, p < 0.001, n = 1180).

Hs-cTnI and hs-cTnT are independently associated with cardiac injury detected with ECG. To test whether the modest hs-cTnI-hs-cTnT correlation also translated into different associations with cardiac injury, we directly compared the associations of hs-cTnI and hs-cTnT with ECG changes indicative of cardiac abnormalities. Univariable associations of hs-cTnI and hs-cTnT with ECG changes indicative of cardiac abnormalities were statistically significant and numerically similar (Table 2, Model 1). Sequential adjustments for demographic variables, eGFR and traditional CVD risk factors did not abrogate the similar associations of both hs-cTn with ECG changes indicative of cardiac abnormalities (OR per 1-SD higher ln hs-cTnI: 1.72, 95% CI 1.40–2.10; OR per 1-SD higher ln hs-cTnT: 1.60, 95% CI 1.22–2.11) (Table 2, Model 4A). Both hs-cTnI and hs-cTnT showed no significant interaction with eGFR on the association with ECG changes indicative of cardiac abnormalities (hs-cTnI * eGFR, pinteraction = 0.991; hs-cTnT * eGFR, pinteraction = 0.409). Results were robust in sensitivity analyses, of which values below the LoD, 20% CV, 10% CV, and LoQ were set equal to these lower limits of measurements (see Supplementary Table S2). However, the association between hs-cTnT and ECG changes indicative of cardiac abnormalities remained not statistically significant when hs-cTnT values below 13 ng/L were set at 13 ng/L (10% CV, LoQ) (see Supplementary Table S2). Results were not materially altered with a more liberal definition of ECG changes indicative of cardiac abnormalities (definition included also borderline Q/QS waves, or ST-segment abnormalities accompanied by abnormal T-waves) (see Supplementary Table S3).

Discordance of hs-cTnI and hs-cTnT assays. Study participants were classified into four groups on the basis of dichotomized hs-cTn concentrations, divided at the sex-specific 75th percentile (hs-cTn, women: 2.20...

| Hs-cTnI | ln, 1-SD increase | p-value | Hs-cTnT | ln, 1-SD increase | p-value |
|--------|-----------------|---------|--------|-----------------|---------|
| model 1 | 1.72 (1.45–2.05) | <0.001  | 1.67 (1.36–2.05) | <0.001  |
| model 2 | 1.72 (1.42–2.09) | <0.001  | 1.56 (1.22–2.01) | 0.001   |
| model 3 | 1.76 (1.45–2.14) | <0.001  | 1.60 (1.22–2.11) | <0.001  |
| model 4A | 1.72 (1.40–2.10) | <0.001  | 1.60 (1.22–2.11) | 0.001   |
| model 4B | 1.89 (1.53–2.34) | <0.001  | 1.65 (1.24–2.20) | 0.001   |

Table 2. Associations of hs-cTnI and hs-cTnT with ECG changes indicative of cardiac abnormalities. Model 1: crude model; model 2: model 1 + sex, age, glucose metabolism status; model 3: model 2 + eGFR; model 4A: model 3 + smoking behavior, total-to-HDL cholesterol ratio, triglyceride levels, lipid-modifying medication, office systolic blood pressure, antihypertensive medication, waist-to-hip ratio, alcohol consumption, educational level; model 4B: model 4A with replacement of office systolic blood pressure by 24h average ambulatory systolic blood pressure. Abbreviations: ECG, electrocardiographic; eGFR, estimated Glomerular Filtration Rate; HDL, high-density lipoprotein; hs-cTnI, high-sensitivity cardiac troponin I; hs-cTnT, high-sensitivity cardiac troponin T.
ng/L; hs-cTnI, men: 3.70 ng/L; hs-cTnT, women: 5.55 ng/L; hs-cTnT, men: 9.36 ng/L). Dichotomization at the 75th percentile was based on a troponin I threshold effect corresponding to the upper quartile. This threshold effect for troponin I was first described in relation to cardiovascular death and heart failure and now further extended in this study in relation to the presence of ECG changes indicative of cardiac abnormalities (Fig. 2). Clinical characteristics of the groups based on sex-specific 75th percentiles (and sex-specific 99th percentiles) per hs-cTn assay are shown in Supplementary Table S4 and S5. The concordance between the two assays was statistically significant but rather weak (Cohen’s κ = 0.397; 95% CI 0.359–0.434), with 22.4% of participants having a discordant classification (Table 3).

We then assessed the associations of dichotomized hs-cTn concentrations with ECG changes indicative of cardiac abnormalities. Both high levels of hs-cTnI and hs-cTnT were strongly associated with ECG changes indicative of cardiac abnormalities (Fig. 3). The strongest association with ECG changes indicative of cardiac abnormalities was observed for participants who had high levels of both hs-cTnI and hs-cTnT (“both hs-cTnI and hs-cTnT high” as compared with the reference category “both hs-cTnI and hs-cTnT low”; OR 3.39, 95% CI 1.94–5.91, p < 0.001) (Fig. 3). As compared with the category “both hs-cTnI and hs-cTnT low”, isolated high levels of troponin I were associated with ECG changes indicative of cardiac abnormalities (OR 1.93, 95% CI 1.01–3.68, p = 0.046), whereas isolated high levels of troponin T were not (OR 1.07, 95% CI 0.49–2.31, p = 0.869) (Fig. 3). These results were robust in a sensitivity analysis in which we used a more liberal definition of ECG changes indicative of cardiac abnormalities (see Supplementary Fig. S2), and when we applied a range of alternative percentile cut-off points (percentile 66th to percentile 90th) to dichotomize cardiac troponin levels (see Supplementary Table S6).

Clinical characteristics of discordantly classified participants. In an exploratory analysis to further investigate the discordance between both hs-cTn assays, we compared clinical parameters of concordant and discordantly classified participants. Discordantly classified participants differed most markedly in estimated glomerular filtration rate (eGFR) and the prevalence of type 2 diabetes mellitus (T2DM): prevalence of eGFR < 60 mL/min/1.73 m² was 7.6% in participants with isolated high hs-cTnI levels compared with 1.5% for participants with isolated high hs-cTnT levels (see Supplementary Table S7). Prevalence of T2DM was 42.7% vs 20.5% in participants with isolated high hs-cTnT levels compared with participants with isolated high hs-cTnI levels, respectively.

Discussion

This study reports four major findings. 1) Hs-cTnI and hs-cTnT were only moderately correlated in the general population. 2) There was substantial discordance between hs-cTnI and hs-cTnT under non-acute conditions. 3) Higher hs-cTnI and hs-cTnT were similarly associated with ECG changes indicative of cardiac abnormalities.
independent of demographic variables, eGFR and CVD risk factors, and 4) isolated high levels of troponin I, but not isolated high levels of troponin T, were associated with ECG changes indicative of cardiac abnormalities, independent of the same risk factors as under 3.

In contrast to the setting of acute coronary syndrome, where hs-cTnI and hs-cTnT are strongly correlated\textsuperscript{13} and are considered diagnostically interchangeable\textsuperscript{18}, recent data suggest a much lower correlation under non-acute conditions such as atrium fibrillation\textsuperscript{20}, stable coronary artery disease\textsuperscript{19}, and chronic kidney disease\textsuperscript{21} (see Supplementary Table S8). This may reflect different mechanisms that drive troponin I and T elevations in the chronic setting. The present results corroborate and extend previously reported data by showing substantial discordance between troponin I and T elevations in a population-based cohort. This study focused on the relationship with cardiac injury, which is a possible mechanism for troponin I and T elevations in the ambulant setting. We found that isolated elevations of troponin I, but not isolated troponin T levels, were associated with ECG changes indicative of cardiac abnormalities. This would suggest that the similar strength of the association for hs-cTnI and hs-cTnT with ECG changes indicative of cardiac abnormalities are due to different underlying mechanisms. Hs-cTnI and hs-cTnT may therefore not be interchangeable as predictor for cardiovascular events and mortality in the ambulant setting, or on the other hand, they may even be complementary to each other. Unraveling the discrepancies between both hs-cTn may contribute to the development of CVD risk stratification algorithms that comprise cardiac biomarkers.

The source of discordant hs-cTnI and hs-cTnT measurements can be analytical or biological. Differences in imprecision between hs-cTnI and hs-cTnT are an unlikely source of the modest correlation between hs-cTnI and hs-cTnT when participants below an LoD of 1.9 ng/L were excluded, which brought the proportion of participants with measurable troponin I concentrations to a similar percentage as the troponin T assay (hs-cTnI 51%, hs-cTnT 54%), the correlation between troponin I and T became even weaker (r = 0.373 vs r = 0.585).

Lack of analytical specificity due to interference of heterophilic or other antibodies is also unlikely to account for the substantial level of discordance and modest correlation between hs-cTnI and hs-cTnT. Hence, we speculate that true biological differences in release and/or elimination underlie the moderate correlation between hs-cTnT and hs-cTnT in the chronic setting. We further explored which variables were associated with the distinct distribution patterns of troponin T and I, and found that a reduced eGFR and T2DM were more prevalent in participants with isolated elevations of troponin T, which is in line with the findings of Hijazi et al.\textsuperscript{20}. Contrary to their findings, we observed no differences in age and proportion of men, but this is probably due to the age limit of 75 years of The Maastricht Study and the fact that we used sex-specific thresholds in our definition of elevated hs-cTn levels, while they did not. Whether these particular traits are mechanistically involved in distinct release and/or clearance patterns of troponin T and I is unknown. In this regard, previous studies have shown a stronger association of hs-cTnT than hs-cTnI with eGFR\textsuperscript{14,21,23-25}, and our results expand these data by showing a higher prevalence of reduced eGFR in participants with isolated high hs-cTnI levels.

This study has several limitations. 1) The cross-sectional nature of our study precludes assessment of longitudinal associations of hs-cTnI and hs-cTnT with incident cardiac morbidity and mortality. Although the results are

---

**Figure 3.** Associations between combined hs-cTn categories and ECG changes indicative of cardiac abnormalities. Definitions of “low” and “high” hs-cTn categories were based on the sex-specific 75th percentiles of hs-cTnI and hs-cTnT (hs-cTnI, women: 2.20 ng/L; hs-cTnI, men: 3.70 ng/L; hs-cTnT, women: 5.55 ng/L; hs-cTnT, men: 9.36 ng/L). Category “low” included participants with hs-cTn levels < the sex-specific 75th percentile and category “high” included participants ≥ the sex-specific 75th percentile. Model was adjusted for sex, age, glucose metabolism status, eGFR, smoking behavior, total-to-HDL cholesterol ratio, triglyceride levels, lipid-modifying medication, office systolic blood pressure, antihypertensive medication, waist-to-hip ratio, alcohol consumption and educational level. Abbreviations: ECG, electrocardiographic; eGFR, estimated Glomerular Filtration Rate; HDL, high-density lipoprotein; hs-cTnI, high-sensitivity cardiac troponin I; hs-cTnT, high-sensitivity cardiac troponin T.
in line with longitudinal associations observed in a cohort with atrium fibrillation, and extend this phenomenon to individuals from a population-based cohort, the next relevant step should be investigating whether troponin I and T are interchangeable predictors for cardiovascular morbidity and mortality in the general population. 2) Only one hs-cTn assay was studied (Abbott), and the lack of standardization of hs-cTn assays precludes extrapolation of our data to other troponin I assays. 3) The study participants were mainly of Caucasian origin, limiting generalizability to other ethnic groups. 4) The definition of cardiac injury is based on ECG data only, without additional information on cardiac ischemia from coronary imaging or echocardiography. Imaging modalities were not yet available in the current dataset. Although the selected ECG criteria indicate the relative likelihood of signs of cardiac ischemia, ECG abnormalities due to for e.g. left ventricular hypertrophy, dilated cardiomyopathy or amyloid cardiomyopathy cannot be excluded. 5) Although hs-cTnI and hs-cTnT were measured with high-sensitivity assays, concentrations were still below the LoB and LoD in a substantial number of participants. 6) To obtain a direct comparison between hs-cTnI and hs-cTnT assay, we corrected in the analysis for assay performance by adjustment of lower limits measurements. However, the lower sensitivity of hs-cTnT assay may have limited to show the association with hs-cTnI levels and ECG changes indicative of cardiac abnormalities.

In conclusion, this study showed a moderate correlation and limited concordance between the hs-cTnI and hs-cTnT assays. We showed that isolated high troponin I levels, but not isolated high troponin T levels, were independently associated with cardiac injury detected with ECG under non-acute conditions. These data suggest that observed associations of hs-cTnI and hs-cTnT with ECG changes indicative of cardiac abnormalities are driven by different mechanisms. This information may benefit future development of CVD risk stratification algorithms, using information from high-sensitivity cardiac troponin I and T assays.

Methods

Study population. We used data from The Maastricht Study, an ongoing observational prospective population-based cohort study. The rationale and methodology have been described previously. In brief, the study focuses on the etiology, pathophysiology, complications and comorbidities of T2DM and is characterized by an extensive phenotyping approach. Eligible for participation were all individuals aged between 40 and 75 years and living in the southern part of the Netherlands. Participants were recruited through mass media campaigns and from the municipal registries and the regional Diabetes Patient Registry via mailings. Recruitment was stratified according to known T2DM status, with an oversampling of individuals with T2DM, for reasons of efficiency. The present report includes cross-sectional data from the first 3451 participants, who completed the baseline survey between November 2010 and September 2013. The examinations of each participant were performed within a time window of three months. The study has been approved by the institutional medical ethical committee (NL31329.068.10) and the Minister of Health, Welfare and Sports of the Netherlands (Permit 131088-105234-PG). All participants gave written informed consent. The study was performed in accordance with the Declaration of Helsinki.

For the present study, individuals with self-reported history of AMI, type 1 diabetes mellitus (T1DM), or missing data on one or more of the independent variables or dependent variables were excluded. Self-reported history of AMI was examined using the Rose questionnaire.

Definition of ECG changes indicative of cardiac abnormalities. A resting 12-lead ECG was obtained using the Mac 5500 ECG system (GE Medical Systems, Milwaukee, Wisconsin, USA). ECG data were processed automatically and coded according to the Minnesota code classification system (Fysiologic ECG Services B.V., Amsterdam, the Netherlands). Outcomes of interests were ECG changes indicative of cardiac abnormalities, classified according to the Whitehall criteria, which are indicating the relative likelihood of signs of cardiac ischemia. ECG changes indicative of cardiac abnormalities were categorized as “probable”, “possible” or “unlikely”. “Probable” was attributed in case of major or medium abnormalities in Q or QS patterns or left bundle branch block (Minnesota coding; 1.1.1-1.2.8 or 7.1.1-7.1.2); “possible” was used for borderline Q/QS waves, or ST-segment abnormalities accompanied by abnormal T-waves (Minnesota coding; 1.3.1, 1.3.2 or 4.1.1, 4.1.2, 4.2, 4.3 accompanied by 5.1, 5.2, 5.3); and “unlikely” for all other Minnesota coding categories (Fig. 4).

Biomarker measurements. Fasting blood samples were collected, centrifuged, and serum was stored in aliquots at −80 °C. Storage time prior to analyses varied from 1–4 years and was identical for hs-cTnI and hs-cTnT. Cardiac troponin I and T were measured in serum using the ARCHITECT i2000 SR analyzer (Abbott Diagnostics, Lake Forest, IL, USA) and Roche Cobas-6000 analyzer (F. Hoffman-La Roche Ltd, Basel, Switzerland), respectively. For hs-cTnI the limit of blank (LoB) ranged from 0.7 to 1.3 ng/L, the LoD was 5 ng/L and the LoQ ranged from 4.0 to 10 ng/L (package insert). For hs-cTnT the LoB was 3 ng/L, the LoD was 5 ng/L and the LoQ was 13 ng/L (package insert). The hs-cTnI assay achieves a 10% CV at 4.7 ng/L and a 20% CV at 1.3 ng/L. The hs-cTnT assay achieves a 10% CV at 13 ng/L and a 20% CV at 6.8 ng/L (package insert). Cystatin C and creatinine were measured in all serum samples using the Roche Cobas-8000 analyzer (F. Hoffman-La Roche Ltd, Basel, Switzerland) and eGFR was calculated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation based on both cystatin C and creatinine.

Potential confounders. We assessed glucose metabolism status, eGFR, smoking behavior, total-to-HDL cholesterol ratio, triglyceride levels, lipid-modifying medication, office or 24 h average ambulatory systolic blood pressure, antihypertensive medication, waist-to-hip ratio, alcohol consumption and educational level as described previously.

Statistical analysis. Continuous variables were expressed as mean and standard deviation (SD), or median and interquartile range (IQR) for non-Gaussian distributions. Categorical data were reported as n (%). The
correlation between natural log-transformed (ln) hs-cTnI and ln hs-cTnT was assessed by Pearson’s correlation test. Cohen’s kappa (κ) was used to assess the concordance between the hs-cTnI and hs-cTnT assays, and the 95% confidence interval (CI) around κ was calculated using bias-corrected accelerated bootstrapping (resampling with replacement: 5000 bootstrap replicates). Multivariable logistic regression analyses were conducted to quantify the associations between both troponins and ECG changes indicative of cardiac abnormalities. In the primary analyses, the ECG abnormality categories “possible” and “unlikely” were combined into a single reference category. To allow for a direct comparison of troponin I and T, the independent variables hs-cTnI and hs-cTnT were tested separately in the statistical models as described below. The hs-cTn values below the LoB were set equal to the LoB value (hs-cTnI, 0.9 ng/L; hs-cTnT, 3 ng/L)/2. For hs-cTnI a LoB value of 0.9 ng/L was chosen to obtain similar proportions for troponin I and T of participants with values above the LoB. Accordingly, hs-cTnI and hs-cTnT were natural log-transformed and examined per 1-SD increase in the regression model. The independent variables (hs-cTnI, hs-cTnT) were analyzed in four different models with sequential adjustment for potential confounders; model 1: crude model; model 2: model 1 + sex, age, glucose metabolism status; model 3: model 2 + eGFR; model 4A: model 3 + smoking behavior, total-to-HDL cholesterol ratio, triglyceride levels, lipid-modifying medication, office systolic blood pressure, antihypertensive medication, waist-to-hip ratio, alcohol consumption, educational level; model 4B: model 4A with replacement of office systolic blood pressure by 24 h average ambulatory systolic blood pressure. Because of the design of The Maastricht Study, we tested for interaction between hs-cTn and glucose metabolism status. Interaction was considered significant when the p value (p_{interaction}) of the interaction term was <0.10. No significant interaction was found for glucose metabolism status and all analyses were, therefore, conducted unstratified. In secondary analyses, we set the hs-cTn values below LoD, 20% CV, 10% CV and LoQ equally to these lower limits of measurements. Furthermore, to allow for a more liberal definition of ECG changes indicative of cardiac abnormalities, “possible” and “probable” were combined as one outcome category and compared with the reference category “unlikely”. All statistical analyses were performed using SPSS for windows 23.0 (IBM Corp., Armonk, NY, USA).

Data Availability. The datasets generated during and/or analysed during the current study are not publicly available due to privacy issues and national laws but are available from the management board of The Maastricht Study on reasonable request under the provision that data may not leave the university/hospital premises.

References
1. Roffi, M. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European heart journal 37, 267–315, doi:10.1093/eurheartj/ehv320 (2016).
2. Apple, F. S., Ler, R. & Murakami, M. M. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. Clin Chem 58, 1574–1581, doi:10.1373/clinchem.2012.192716 (2012).
3. Apple, F. S., Steffen, L. M., Pearce, L. A., Murakami, M. M. & Luepker, R. V. Increased cardiac troponin I as measured by a high-sensitivity assay is associated with high odds of cardiovascular death: the Minnesota Heart Survey. Clin Chem 58, 930–935, doi:10.1373/clinchem.2011.192716 (2012).
4. Eggers, K. M., Venge, P., Lindahl, B. & Lind, L. Cardiac troponin I levels measured with a highly sensitive assay and cardiac structure and mortality risk in the general population. Journal of the American College of Cardiology 61, 1906–1913, doi:10.1016/j.jacc.2013.07.048 (2013).
5. de Lemos, J. A. et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 304, 2503–2512, doi:10.1001/jama.2010.1768 (2010).
6. Husseini, A. A. et al. Cardiomyocyte injury assessed by a highly sensitive troponin assay and sudden cardiac death in the community: the Cardiovascular Health Study. Journal of the American College of Cardiology 62, 2112–2120, doi:10.1016/j.jacc.2013.07.049 (2013).
7. Eggers, K. M. et al. High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men. American heart journal 166, 541–548, doi:10.1016/j.ahj.2013.07.004 (2013).
8. Oluleye, O. W. et al. Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality. Ann Epidemiol 23, 66–73, doi:10.1016/j.annepidem.2012.11.004 (2013).
9. Masson, S. et al. The fibroblast growth factor-23 and Vitamin D emerge as nontraditional risk factors and may affect cardiovascular risk. J Intern Med 277, 318–330, doi:10.1111/j.1468-5800.2013.02923.x (2013).
10. Neumann, J. T. et al. Comparison of three troponins as predictors of future cardiovascular events—prospective results from the FINRISK and Biomarker studies. PloS one 9, e90063, doi:10.1371/journal.pone.0090063 (2014).
11. Wang, T. J. et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 126, 1596–1604, doi:10.1161/CIRCULATIONAHA.112.129477 (2012).
12. Omland, T. et al. Impact of sex on the prognostic value of high-sensitivity cardiac troponin I in the general population: the HUNT study. Clin Chem 61, 646–656, doi:10.1373/clinchem.2014.234369 (2015).
13. Haal, P. et al. Risk stratification in patients with acute chest pain using three high-sensitivity cardiac troponin assays. European heart journal 35, 365–375, doi:10.1093/eurheartj/ehz118 (2014).
14. Cardinaels, E. P. et al. Clinical Interpretation of Elevated Concentrations of Cardiac Troponin T, but Not Troponin I, in Nursing Home Residents. J Am Med Dir Assoc 16, 884–891, doi:10.1016/j.jamda.2015.06.026 (2015).
15. Sze, J., Mooney, J., Barzi, F., Hillis, G. S. & Chow, C. K. Cardiac Troponin and its Relationship to Cardiovascular Outcomes in Community Populations - A Systematic Review and Meta-analysis. Heart, lung & circulation 25, 217–228, doi:10.1016/j.hlc.2015.09.001 (2016).
16. Thorsteinsdottir, I. et al. High-Sensitivity Cardiac Troponin I Is a Strong Predictor of Cardiovascular Events and Mortality in the AGES-Reykjavik Community-Based Cohort of Older Individuals. Clin Chem 62, 623–630, doi:10.1373/clinchem.2015.250811 (2016).
17. Blankenberg, S. et al. Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. European heart journal 37, 2428–2437, doi:10.1093/eurheartj/ehw172 (2016).
18. Rubini Gimenez, M. et al. Direct comparison of high-sensitivity-cardiac troponin I vs. T for the early diagnosis of acute myocardial infarction. European heart journal 35, 2303–2311, doi:10.1093/eurheartj/ehu188 (2014).
19. Omland, T. et al. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. Journal of the American College of Cardiology 61, 1240–1249, doi:10.1016/j.jacc.2012.12.026 (2013).
20. Hijazi, Z. et al. Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. Clin Chem 61, 368–378, doi:10.1373/clinchem.2014.226936 (2015).
21. deFilippi, C. et al. Interpreting cardiac troponin results from high-sensitivity assays in chronic kidney disease without acute coronary syndrome. Clin Chem 58, 1342–1351, doi:10.1093/clinchem/hvs322 (2012).
22. Zhang, Z. M., Prineas, R. J. & Eaton, C. B. Evaluation and comparison of the Minnesota Code and Novacode for electrocardiographic QS-T wave abnormalities for the independent prediction of heart failure, incidence, and total mortality (from the Women’s Health Initiative). The American journal of cardiology 106, 18–25 e12, doi:10.1016/j.amjcard.2010.02.007 (2010).
23. Lippi, G. & Cervellin, G. High-sensitivity troponin I is more susceptible than high-sensitivity troponin T impaired renal function. The American journal of cardiology 112, 1985, doi:10.1016/j.amjcard.2013.10.003 (2013).
24. Bjurman, C. et al. High-sensitive cardiac troponin, NT-proBNP, hFABP and copeptin levels in relation to glomerular filtration rates and a medical record of cardiovascular disease. Clinical biochemistry 48, 302–307, doi:10.1016/j.clinbiochem.2015.01.008 (2015).
25. Martens, R. J. et al. Estimated Glomerular Filtration Rate and Albuminuria Are Associated with Biomarkers of Cardiac Injury in a Population-Based Cohort Study: The Maastricht Study. Clin Chem 63, 887–897, doi:10.1373/clinchem.2016.266031 (2017).
26. Schram, M. T. et al. The Maastricht Study: an extensive phenotyping study on determinants of type 2 diabetes, its complications and its comorbidities. European journal of epidemiology 29, 439–451, doi:10.1007/s10654-014-9889-0 (2014).
27. World Medical, A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310, 2191–2194, doi:10.1001/jama.2013.281053 (2013).
28. Leng, G. C. & Fowkes, F. G. The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. Journal of clinical epidemiology 45, 1101–1109 (1992).
29. Prineas, R. J., Crow, R. S. & Zhang, Z. M. (Springer-Verlag London, 2010).
30. Kors, J. A. et al. Validation of a new computer program for Minnesota coding. Journal of electrocardiology 29(Suppl), 83–88 (1996).
31. Kors, J. A., Crow, R. S., Hannan, P. J., Rautaharju, P. M. & Folsom, A. R. Comparison of computer-assigned Minnesota Codes with the visual standard method for new coronary heart disease events. American journal of epidemiology 151, 790–797 (2000).
32. Keen, H., Morrish, N. & Lee, E. T. An analysis of serial Minnesota ECC code changes in the London cohort of the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44(Suppl 2), S72–S77 (2001).
33. Koerbin, G., Tate, J. R. & Hickman, P. E. Analytical characteristics of the Roche highly-sensitive troponin T assay and its application to a cardio-healthy population. Ann Clin Biochem 47, 524–528, doi:10.12823/ach.2010.010033 (2010).
34. Inker, L. A. et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. The New England journal of medicine 367, 20–29, doi:10.1056/NEJMoa1114248 (2012).
35. Spauwen, P. J. et al. Both Low and High 24-Hour Diastolic Blood Pressure Are Associated With Worse Cognitive Performance in Type 2 Diabetes: The Maastricht Study. Diabetes care 38, 1473–1480, doi:10.2337/dc14-2502 (2015).
36. Martens, R. J. et al. Estimated GFR, Albuminuria, and Cognitive Performance: The Maastricht Study. American journal of kidney diseases: the official journal of the National Kidney Foundation 69, 179–191, doi:10.1053/j.ajkd.2016.04.017 (2017).

Acknowledgements
The authors would like to thank V.W. Kleijnen for the technical laboratory support. The authors thank the staff and participants of The Maastricht Study for their important contribution. The hs-cTnl kits were provided by Abbott Diagnostics. This study was supported by the European Regional Development Fund via OP-Zuid, the Province of Limburg, the Dutch Ministry of Economic Affairs (grant 31 O 041), Stichting De Weijerhorst (Maastricht, the Netherlands), the Pearl String Initiative Diabetes (Amsterdam, the Netherlands), the Cardiovascular Center (CVC, Maastricht, the Netherlands), Cardiovascular Research Institute Maastricht (CARIM, Maastricht, the Netherlands), School for Public Health and Primary Care (CAPHRI, Maastricht, the Netherlands), School for Nutrition, Toxicology and Metabolism (NUTRIM, Maastricht, the Netherlands), Stichting Annadal (Maastricht, the Netherlands), Health Foundation Limburg (Maastricht, the Netherlands) and by unrestricted grants from Janssen-Cilag B.V. ( Tilburg, the Netherlands), Novo Nordisk Farma B.V. (Alphen aan den Rijn, the Netherlands) and Sanofi-Aventis Netherlands B.V. (Gouda, the Netherlands).

Author Contributions
Conception and design of the study, interpretation of the data and drafting of the manuscript: D.M.K., R.J.H.M., R.M.A.H. and S.J.R.M. Statistical analysis: D.M.K., R.J.H.M. and F.E.S.T. Critically reviewing the manuscript and providing important intellectual content: M.P.v.D.-V., J.P.K., C.D.A.S., N.C.S., P.C.D., M.T.S., C.J.H.v.d.K., S.J.S.S., J.D.E.v.S., A.A.K., and O.B.
